Table 3.
Frontline trials of asparaginase in adults with ALL
| Study | Number of patients | Patient age range (years) | Asparaginase dose | Asparaginase preparation | CR rate | Survival |
|---|---|---|---|---|---|---|
| Hoelzer et al31 | 162 | 15–65 | 5,000 IU/m2 ×14 doses during induction | E. coli l-asparaginase | 78% | Median OS =26 months Median remission duration =20 months |
| DeAngelo et al32 | 92 | 18–50 | Starting dose of 12,500 IU/m2 IM pharmacokinetically dose-adjusted given weekly for 30 weeks | E. coli l-asparaginase | 85% | DFS =69%, OS =67% at 4 years |
| Douer et al34 | 51 | 18–57 | 2,000 IU/m2 for a total of six doses | Pegaspargase | 96% | DFS =58%, OS =51% at 7 years |
| Rijneveld et al35 (for the Dutch- Belgian HOVON study group) | 54 | 17–40 | 6,000 IU/m2 for a total of 21 doses | E. coli l-asparaginase | 91% | EFS =66%, OS =72% at 32 months |
| Huguet et al36 (for the GRAALL) | 225 | 15–60 | 6,000 IU/m2 for a total of eight doses | E. coli l-asparaginase | 93.5% | EFS =55%, OS =60% at 42 months |
Abbreviations: CR, complete remission; DFS, disease-free survival; EFS, event-free survival; IM, intramuscular; OS, overall survival; ALL, acute lymphoblastic leukemia.